EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Phosphatidylcholine in bile‐derived small extracellular vesicles as a novel biomarker of cholangiocarcinoma

Ryuta Muraki iD, Yoshifumi Morita, Shinya Ida, Ryo Kitajima, Satoru Furuhashi, Makoto Takeda iD, Hirotoshi Kikuchi, Yoshihiro Hiramatsu, Yusuke Takanashi, Yasushi Hamaya, Ken Sugimoto, Jun Ito und 6 weitere

Cancer Medicine · 2023-06 · 12 (12) · 13007-13018

DOI: 10.1002/cam4.5973 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, online erschienen am 25.04.2023. Verfasst von Ryuta Muraki und 17 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan. Hauptthemen laut MEDLINE: Cholangiocarcinoma, Bile Duct Neoplasms, Extracellular Vesicles. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Owing to the lack of definite diagnostic modalities, it is challenging to distinguish malignant cases of cholangiocarcinoma (CCA), which often causes biliary tract obstruction, from benign ones. Here, we investigated a novel lipid biomarker of CCA in bile‐derived small extracellular vesicles (sEVs) and developed a simple detection method for clinical application.

Methods

Bile samples from seven patients with malignant diseases (hilar CCA = 4, distal CCA = 3) and eight patients with benign diseases (gallstones = 6, primary sclerosing cholangitis = 1, autoimmune pancreatitis = 1) were collected through a nasal biliary drainage tube. sEVs were isolated via serial ultracentrifugation and characterized using nanoparticle tracking analysis, transmission electron microscopy, and immunoblotting (with CD9, CD63, CD81, and TSG101). Comprehensive lipidomic analysis was performed using liquid chromatography–tandem mass spectrometry. Using a measurement kit, we further confirmed whether lipid concentrations could be used as a potential CCA marker.

Results

Lipidomic analysis of bile sEVs in the two groups identified 209 significantly increased lipid species in the malignant group. When focusing on lipid class, phosphatidylcholine (PC) level was 4.98‐fold higher in the malignant group than in the benign group (P = 0.037). The receiver operating characteristic (ROC) curve showed a sensitivity of 71.4%, a specificity of 100%, and an area under the curve (AUC) of 0.857 (95% confidence interval [CI]:0.643–1.000). Using a PC assay kit, the ROC curve showed a cutoff value of 16.1 μg/mL, a sensitivity of 71.4%, a specificity of 100%, and an AUC of 0.839 (95% CI: 0.620–1.000).

Conclusion

PC level in sEVs from human bile is a potential diagnostic marker for CCA and can be assessed by a commercially available assay kit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholangiocarcinomaBile Duct NeoplasmsExtracellular VesiclesHumansBilePhosphatidylcholinesBiomarkersBile Ducts, IntrahepaticBiomarkers, Tumor

Stichwörter der Autor:innen

bilebiomarkercholangiocarcinomaextracellular vesiclephosphatidylcholine

Substanzen

PhosphatidylcholinesBiomarkersBiomarkers, Tumor

Autor:innen und Institutionen

  • Second Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Cellular and Molecular Anatomy, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Department of Perioperative Functioning Care & Support, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • First Department of Surgery, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • First Department of Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.
  • Second Department of Internal Medicine, Hamamatsu University School of Medicine, Hamamatsu, Japan.

ORCID-Profile: Ryuta Muraki, Makoto Takeda

Förderung

  • Japan Agency for Medical Research and Development

Zitieren

APA

Muraki, R., Morita, Y., Ida, S., Kitajima, R., Furuhashi, S., Takeda, M., Kikuchi, H., Hiramatsu, Y., Takanashi, Y., Hamaya, Y., Sugimoto, K., Ito, J., Kawata, K., Kawasaki, H., Sato, T., Kahyo, T., Setou, M., & Takeuchi, H. (2023). Phosphatidylcholine in bile‐derived small extracellular vesicles as a novel biomarker of cholangiocarcinoma. Cancer Medicine, 12(12), 13007-13018. https://doi.org/10.1002/cam4.5973

Vancouver

Muraki R, Morita Y, Ida S, Kitajima R, Furuhashi S, Takeda M, et al. Phosphatidylcholine in bile‐derived small extracellular vesicles as a novel biomarker of cholangiocarcinoma. Cancer Medicine. 2023;12(12):13007-13018. doi:10.1002/cam4.5973

BibTeX
@article{Muraki2023,
  author = {Muraki, Ryuta and Morita, Yoshifumi and Ida, Shinya and Kitajima, Ryo and Furuhashi, Satoru and Takeda, Makoto and Kikuchi, Hirotoshi and Hiramatsu, Yoshihiro and Takanashi, Yusuke and Hamaya, Yasushi and Sugimoto, Ken and Ito, Jun and Kawata, Kazuhito and Kawasaki, Hideya and Sato, Tomohito and Kahyo, Tomoaki and Setou, Mitsutoshi and Takeuchi, Hiroya},
  title = {Phosphatidylcholine in bile‐derived small extracellular vesicles as a novel biomarker of cholangiocarcinoma},
  journal = {Cancer Medicine},
  year = {2023},
  volume = {12},
  number = {12},
  pages = {13007--13018},
  doi = {10.1002/cam4.5973}
}
Kostenlos starten →